Stephanie Price
Psychiatry · Cary, NCNPI 1578097077
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 129 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,024 and has fallen 90.9% since, to $93 in 2025.
Across 129 payments — averaging $15.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$429
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$324
- Bausch Health US, LLC$155
- Takeda Pharmaceuticals U.S.A., Inc.$123
- Lundbeck LLC$122
- Vanda Pharmaceuticals Inc.$119
- plus $718 from 13 others
What the payments were for
- Food & beverage$1,990100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 38 | $429 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 21 | $324 |
| Bausch Health US, LLC | 11 | $155 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $123 |
| Lundbeck LLC | 7 | $122 |
| Vanda Pharmaceuticals Inc. | 5 | $119 |
| Otsuka America Pharmaceutical, Inc. | 6 | $106 |
| Johnson & Johnson | 5 | $94 |
| Acadia Pharmaceuticals Inc | 4 | $84 |
| Teva Pharmaceuticals USA, Inc. | 3 | $81 |
| Neurocrine Biosciences, Inc. | 5 | $74 |
| Idorsia Pharmaceuticals US Inc | 4 | $73 |
| Avanir Pharmaceuticals, Inc. | 5 | $71 |
| Corium, LLC | 2 | $36 |
| Alkermes, Inc. | 2 | $32 |
| Almatica Pharma LLC | 2 | $29 |
| Gilead | 1 | $14 |
| Neos Therapeutics, LP | 1 | $13 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$1,990 in reported general payments places this provider in the 80th percentile of 1,108 psychiatry providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 18 | $593 |
| Mirtazapine | 14 | $286 |
| Buspirone Hcl | 25 | $265 |
| Bupropion XlBupropion Hcl | 12 | $241 |
| Aripiprazole | 25 | $232 |
| Divalproex Sodium | 14 | $119 |
| Escitalopram Oxalate | 18 | $78 |
| Trazodone Hcl | 11 | $65 |
| Citalopram HbrCitalopram Hydrobromide | 13 | $35 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Cary
- Haresh TharwaniCary$159K
- Craig ChepkeHuntersville$4.1M
- Mark ReynoldsDurham$3.2M
- James BarkerHickory$2.1M
- Brian FarahWinston Salem$605K
- Krishna TalluriMorrisville$591K
- Ramesh GihwalaGastonia$545K
- Keshavpal ReddyGreensboro$480K
- Robert MilletRaleigh$476K
- Steven SzaboDurham$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.